Site-Selective Alkenylation of δ-C(sp<sup>3</sup>)–H Bonds with Alkynes via a Six-Membered Palladacycle
作者:Jing-Wen Xu、Zhuo-Zhuo Zhang、Wei-Hao Rao、Bing-Feng Shi
DOI:10.1021/jacs.6b05978
日期:2016.8.31
kinetically favored five-membered cyclometalated intermediate. Here, we report the first site-selective alkenylation of δ-C(sp(3))-H in the presence of more accessible γ-C(sp(3))-H bonds via a kinetically less favored six-membered palladacycle. A wide range of functional groups are tolerated, and the unique protocol can be applied to the synthesis of chiral piperidines. Moreover, mechanistic insights have
CeO2 acted as a reusable and effective catalyst for the hydration of various nitriles to amides in water under neutral conditions at low temperature (30–100 °C). CeO2 showed notable substrate specificity for nitriles that have a heteroatom adjacent to the α‐carbon atom of the CN group (see scheme).
CeO 2 充当可重用且有效的催化剂,可在低温(30–100°C)下在中性条件下将水中的各种腈水合成酰胺。CeO 2对腈具有显着的底物特异性,腈具有与CN基团的α-碳原子相邻的杂原子(请参见方案)。
Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
申请人:Sekiguchi Yoshinori
公开号:US20080090863A1
公开(公告)日:2008-04-17
The present invention encompasses novel substituted pyridine compounds of Formula (I):
which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
Benzamide factor VIIa inhibitors useful as anticoagulants
申请人:Bristol-Myers Squibb Company
公开号:US08222453B2
公开(公告)日:2012-07-17
The present invention provides novel benzamide derivatives of Formula (I):
or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
LIPOPROTEIN ADSORBENT AND LIPOPROTEIN ADSORBER MADE WITH THE USE OF THE SAME
申请人:KANEKA CORPORATION
公开号:EP1008383A1
公开(公告)日:2000-06-14
The present invention has its objects to provide an adsorbent capable of efficiently adsorbing and removing LDL and VLDL if from various lipoprotein-containing solutions, as well as a lipoprotein adsorbed in which said adsorbent is used.
This invention is related to a lipoprotein adsorbent which has ligands comprising an atomic group wherein an aromatic group having a logarithmic value of the partition coefficient (log P) in the water-octanol system of 0 to 3.2 and having a substituent at the m-position is bonded directly or via an atom to a nitrogen atom or another atomic group containing an aromatic ring bonded via a carbonyl group to a nitrogen atom and having a log P of 0 to 3.2 at least on a part of the surface of a water insoluble carrier; and a lipoprotein adsorber containing the above adsorbent therein.